Longboard Pharmaceuticals — Technical Presentation (January 2024)
21 slides from Longboard Pharmaceuticals's technical presentation, Jan 2, 2024
Slide 1: PACIFIC Study Topline Data
Exhibit 99.2 PACIFIC Study Topline Data JANUARY 2, 2024 1 LONGBOARD PHARMACEUTICALS
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: the potential of LP352 (including to be best-in-class, to change the DEE landscape, to serve as the cornerstone
Slide 3: PACIFIC Study Topline Data
PACIFIC Study Topline Data JANUARY 2, 2024 3 LONGBOARD PHARMACEUTICALS
Slide 4: Bexicaserin Has the Potential to Change the DEE Landscape
Bexicaserin Has the Potential to Change the DEE Landscape • Bexicaserin provides the cornerstone to potentially build a world-class epilepsy 53.3% franchise • Studies to date highlight bexicaserin as Median Reduction in potentially best-in-class Seizures* • Composition of matter IP protection throug
Slide 5: Bexicaserin (LP352) Ph 1b/2a PACIFIC Study in Participants with DEEs
Bexicaserin (LP352) Ph 1b/2a PACIFIC Study in Participants with DEEs Screening Randomization & Maintenance* Down- Follow-up Period Up-Titration Titration Period 5 Wks Days 1-15 Days 16-75 Days 76- 30 Days 80/90** LP352 (n=43) 6 mg 9 mg 12 mg Participant remains on 6, 9 or Open- 12 mg based on tolera
Slide 6: Diagnostic Eligibility Criteria: Dravet Syndrome, Lennox-Gastaut Syndrome (LGS) and Other DEEs
Diagnostic Eligibility Criteria: Dravet Syndrome, Lennox-Gastaut Syndrome (LGS) and Other DEEs All participants: Treatment-resistant countable motor seizures with average of ≥ 4 observed/countable motor seizures per 4- week period during 12 weeks before screening while on stable ASM treatment Dravet
Slide 7: Topline Participant Disposition & Safety Results Summary
Topline Participant Disposition & Safety Results Summary 7 LONGBOARD PHARMACEUTICALS
Slide 8: Demographics, Baseline Characteristics & Concomitant Medications
Demographics, Baseline Characteristics & Concomitant Medications Bexicaserin Placebo Overall Parameter n(%) Statistics (N=43) (N=9) (N=52) Mean 23.8 26.7 24.3 Age (Years) Standard Deviation 9.62 7.73 9.31 Median 23.0 23.0 23.0 Min, Max 12, 55 19, 41 12, 55 Male 21 (48.8) 7 (77.8) 28 (53.8) Sex Femal
Slide 9: Participant Disposition
Participant Disposition n(%) Overall Dravet Syndrome LGS DEE Other Bexicaserin Placebo Bexicaserin Placebo Bexicaserin Placebo Bexicaserin Placebo Safety Set 43 (100) 9 (100) 4 (9.3) 0 24 (55.8) 5 (55.6) 15 (34.9) 4 (44.4) Full Analysis Set 35 (81.4) 9 (100) 3 (7.0) 0 17 (39.5) 5 (55.6) 15 (34.9) 4
Slide 10: 86% of Bexicaserin Treated Participants Achieved 12 mg Dose
86% of Bexicaserin Treated Participants Achieved 12 mg Dose Highest tolerated dose achieved for the Maintenance Period n(%) Bexicaserin (LP352) Placebo Overall All Participants 35 9 44 6 mg 1 (2.9) 0 1 (2.3) 9 mg 4 (11.4) 0 4 (9.1) 12 mg 30 (85.7) 9 (100) 39 (88.6) Dravet Syndrome 3 0 3 6 mg 0 0 0 9
Slide 11: Safety Results Summary
Safety Results Summary n(%) Bexicaserin Placebo Overall (N=43) (N=9) (N=52) Participants with any TEAEs 35 (81.4) 8 (88.9) 43 (82.7) Drug-Related TEAEs 28 (65.1) 3(33.3) 31 (59.6) TEAEs Leading to Discontinuation 9 (20.9) 0 9 (17.3) TEAEs Leading to Discontinuation (Titration) 7 (16.3) 0 7 (13.5) TE
Slide 12: Topline Efficacy Results
Topline Efficacy Results 12 LONGBOARD PHARMACEUTICALS
Slide 13: Bexicaserin Achieved Median Seizure Reduction of 53.3% Compared to 20.8% for Placebo
Bexicaserin Achieved Median Seizure Reduction of 53.3% in Countable Motor Seizures Compared to 20.8% for Placebo Across the DEE Study Population Δ 32.5% 0% Median Percent Change from Baseline -10% -20% -20.8% -30% -40% -50% -53.3% Bexicaserin (LP352) -60% Placebo 13 LONGBOARD PHARMACEUTICALS Bexicas
Slide 14: Bexicaserin Achieved Median Seizure Reduction Across Dravet, LGS, DEE Other Cohorts
Bexicaserin Achieved Median Seizure* Reduction Across Dravet, LGS, DEE Other Cohorts Δ 27.3% Δ 28.6% -5% Median Percent Change from Baseline -15% -20.8% -25% -32.6% -35% -45% -48.1% -55% -61.2% -65% -72.1% -75% Bexicaserin (LP352) Placebo Dravet LGS DEE Other 14 LONGBOARD PHARMACEUTICALS *Countable
Slide 15: PACIFIC Results Pave the Way for Global Phase 3 Program
PACIFIC Results Pave the Way for Global Phase 3 Program PACIFIC demonstrated meaningful efficacy results across a broad DEE population as well as in individuals with LGS and Dravet Bexicaserin (LP352) achieved a median percent reduction from baseline in seizure frequency during the treatment period
Slide 16: Summary & Next Steps
Summary & Next Steps 16 LONGBOARD PHARMACEUTICALS
Slide 17: 4 DEE Syndromes Have Approved Therapies; 20+ Have None
4 DEE Syndromes Have Approved Therapies; 20+ Have None “Approved 4” DEE Prevalence (US) Other DEEs ~48,000 ~50,000 • DUP15q • Rett Syndrome • SCN2A related epilepsies • Ohtahara Syndrome • SCN8A related epilepsies • PCDH19 • KCNQ2 related epilepsies • EE w/ Continuous • KCNQ3 related epilepsies Spik
Slide 18: Competitive Landscape: Median Seizure Reduction for Bexicaserin and Approved Compounds
Competitive Landscape: Median Seizure Reduction for Bexicaserin and Approved Compounds in Dravet and LGS Dravet Syndrome1,3,4 Lennox-Gastaut Syndrome2,3,4 Δ 56% Δ 26% Δ 22% Δ 27% Δ 25% Δ 19% Δ 22% 0% 0% -7% Median Percent Change from Baseline -13% Median Percent Change from Baseline -10% N=87 -19% N
Slide 19: Significant Unmet Need in DEEs (Beyond Dravet and LGS)
Significant Unmet Need in DEEs (Beyond Dravet and LGS) “Other DEEs” With No Specifically “DEE Other” in PACIFIC “Other DEEs” with Specifically Approved Approved Therapies Therapies • DUP15q DEE Other CDD TSC • SCN2A related epilepsies Δ 28% Δ 24% Δ 22% • SCN8A related epilepsies • KCNQ2 related epil
Slide 20: Bexicaserin Has the Potential to Change the DEE Landscape
Bexicaserin Has the Potential to Change the DEE Landscape • Bexicaserin provides the cornerstone to potentially build a world-class epilepsy 53.3% franchise • Studies to date highlight bexicaserin as Median Reduction in potentially best-in-class Seizures* • Composition of matter IP protection throug
Slide 21: Thank you
Thank you Nasdaq: LBPH IR@LONGBOARDPHARMA.COM 21 LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals — Technical Presentation (January 2024) on 6ix